Enspire DBS Therapy, a clinical-stage medical technology company developing implantable neuromodulation therapies for post-stroke recovery, has secured USD 10.3 million in a Series B1 financing round. The round was led by new investor Genesys Capital, with participation from existing backers Cleveland Clinic and JobsOhio Ventures.

The proceeds will be used to continue patient enrollment in the multicentre restore pivotal clinical trial, which is evaluating deep brain stimulation combined with structured rehabilitation (DBS + Rehab) in patients with chronic upper-extremity impairment following stroke. The study is designed to generate the long-term safety and effectiveness data needed to support a future FDA marketing authorisation. Interim clinical results are expected in mid-2027.

According to Enspire, the therapy aims to address the significant unmet need in post-stroke rehabilitation by enhancing neuroplasticity and functional recovery in patients with long-term neurological deficits. If successful, the approach could represent a first-in-class brain stimulation therapy for stroke recovery.

As part of the financing, Jamie Stiff, Managing Partner at Genesys Capital, has joined Enspire’s Board of Directors, further strengthening the company’s leadership as it advances through pivotal clinical development.